Edaravone
Indications
Edaravone is used for:
Amyotrophic lateral sclerosis (ALS), Neurological symptoms
Adult Dose
Intravenous
Adult: 30 mg of Edaravone IV two times a day.
The course of treatment should be less than 2 weeks.
IV infusion of Edaravone should be considered within 24 hours of onset of symptoms.
Child Dose
Renal Dose
Administration
Reconstituted with normal saline before administration.
Contra Indications
Hypersensitivity
Precautions
Caution with mild to moderate renal insufficiency, cardiac disorders, hepatic failure.
Pregnancy-Lactation
Pregnancy
There are no adequate data on the developmental risk associated with use in pregnant women
In animal studies, administration to pregnant rats and rabbits resulted in adverse developmental effects (increased mortality, decreased growth, delayed sexual development, and altered behavior) at clinically relevant doses; most of these effects occurred at doses that were also associated with maternal toxicity
Lactation
Unknown if distributed in human breast milk
Excreted in the milk of lactating rats
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Interactions
Edaravone should not be used concomitantly with diazepam, phenytoin, cefotetan, piperacillin and cefazolin.
Adverse Effects
Side effects of Edaravone :
Acute renal failure, liver dysfunction, acute allergic reactions, disseminated intravascular coagulation, thrombocytopenia, and leukocytopenia, are occasionally observed by >5% of patients during edaravone treatment
Mechanism of Action
As a free radical scavenger, Edaravone lowers N- acetyl aspartate (NAA) and reduce cerebral blood flow into the cerebral infarct areas. The mechanism of Edaravone action reduces cerebral edema and cerebral infarction and lowers lipid-peroxidation induced neuronal death and subsequent oxidative stress of endothelial cells of the brain.